An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.
View the full Corporate Spotlight
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| RCE | Ann: Quarterly Activities/Appendix 4C Cash Flow Report | 15:54 | 57 | 14K | |||
|
|||||||
| RCE Biotech | MST Financial Valuation $2.62 - from RCE website. | 15/08/25 | 0 | 214 | |||
|
|||||||
| RCE Biotech | RCE Why Diabetes makes infections harder to treat | 15/08/25 | 0 | 141 | |||
|
|||||||
| RCE | AI designs new antibiotics to combat superbugs | 15/08/25 | 0 | 142 | |||
|
|||||||
| RCE | Recce answers US Defence call with 'highly effective' R327 gel for burn wounds | 14/08/25 | 4 | 841 | |||
|
|||||||
| RCE Biotech | RCE Mechanism for action | 13/08/25 | 0 | 207 | |||
|
|||||||
| RCE Biotech | RCE Update | 13/08/25 | 0 | 186 | |||
|
|||||||
| RCE Biotech | RCE Burn Wounds information | 13/08/25 | 0 | 154 | |||
|
|||||||
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
| View More | |||||
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
-0.005(1.22%) |
Mkt cap ! $117.1M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.5¢ | 40.5¢ | $15.06K | 36.75K |
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3000 | 40.0¢ |
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 10000 | 1 |
| Last trade - 15.39pm 20/08/2025 (20 minute delay) ? |
|
|||||
|
Last
40.0¢ |
Change
-0.005 ( 2.44 %) |
||||
| Open | High | Low | Volume | ||
| 42.5¢ | 42.5¢ | 40.0¢ | 23935 | ||
| Last updated 15.58pm 20/08/2025 ? | |||||
| RCE (ASX) Chart |
